Enzo Biochem Stock Story

ENZ -  USA Stock  

USD 2.99  0.02  0.66%

It appears Enzo Biochem will continue to recover much faster as its share price surged up 0.31% today. The company current daily volatility is 5.59 percent, with a beta of 1.62 and an alpha of 0.17 over DOW. As many baby boomers are still indifferent towards healthcare, it makes sense to break down Enzo Biochem. Why are we still confident in our projection for a recovery.
Published over a week ago
View all stories for Enzo Biochem | View All Stories
Should you buy Enzo Biochem after the current volatility rise?
Enzo Biochem has roughly 44.54 M in cash with (11.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92.
We provide trade advice to complement the prevailing expert consensus on Enzo Biochem. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in Enzo Biochem, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Enzo Biochem along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Enzo Biochem's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Enzo Biochem in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Enzo Biochem. Your research has to be compared to or analyzed against Enzo Biochem's peers to derive any actionable benefits. When done correctly, Enzo Biochem's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Enzo Biochem.

How important is Enzo Biochem's Liquidity

Enzo Biochem financial leverage refers to using borrowed capital as a funding source to finance Enzo Biochem ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Enzo Biochem financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Enzo Biochem's total debt and its cash.

How Enzo Biochem utilizes its cash?

To perform a cash flow analysis of Enzo Biochem, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Enzo Biochem is receiving and how much cash it distributes out in a given period. The Enzo Biochem cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Enzo Biochem Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Enzo Biochem reported Net Cash Flow from Operations of (19.76 Million) in 2020

Enzo Biochem Correlation with Peers

Investors in Enzo Biochem can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Enzo Biochem. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Enzo Biochem and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Enzo Biochem is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Enzo Biochem for more details

Purchase by Harbert Management Corp of 409200 shares of Enzo Biochem

Legal trades by Enzo Biochem insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Enzo Biochem insider trading alert for perchase of common stock by Harbert Management Corp, the corporate stakeholder, on 18th of May 2021. This event was filed by Enzo Biochem Inc with SEC on 2019-07-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Enzo Biochem appears to be risky, given 3 months investment horizon. Enzo Biochem secures Sharpe Ratio (or Efficiency) of 0.0478, which denotes the company had 0.0478% of return per unit of risk over the last 3 months. Our standpoint towards predicting the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. We have found twenty-eight technical indicators for Enzo Biochem, which you can use to evaluate the future volatility of the firm. Please utilize Enzo Biochem's Coefficient Of Variation of 1685.89, downside deviation of 3.32, and Mean Deviation of 2.88 to check if our risk estimates are consistent with your expectations.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Some Enzo Biochem technical indicators suggest bounce back

Current Information Ratio is up to 0.04. Price may slide again. Enzo Biochem shows above-average downside volatility for the selected time horizon. We advise investors to inspect Enzo Biochem further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Enzo Biochem future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enzo Biochem's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enzo Biochem's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Enzo Biochem

While many other companies within the diagnostics & research industry are still a little expensive, even after the recent corrections, Enzo Biochem may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take up nor exit any shares of Enzo Biochem at this time. The Enzo Biochem risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Enzo Biochem.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Enzo Biochem. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com